June 15, 2017
Alpha Cancer Technologies Inc. Reports Acceptance of the Abstract of Study of ACT-101 in a Model of Inflammatory Bowel Disease to the World Congress of Gastroenterology at ACG 2017
Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that the abstract describing the results of a pre-clinical study of the efficacy of ACT-101 in a mouse model of inflammatory bowel disease (IBD) has been submitted for presentation at the World Congress of Gastroenterology at ACG 2017 to be held in Orlando, Florida October 13-18, 2017.
May 15, 2017
Alpha Cancer Technologies Inc. Announces Presentation of ACT-101 Study Results in Pre-Clinical Model of Myasthenia Gravis (MG) at the 13th International Conference on Myasthenia Gravis and Related Disorders
Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that an abstract highlighting the results of a study of ACT-101 (recombinant human alpha fetoprotein or AFP) in the treatment of myasthenia gravis has been presented at the 13th International Conference on Myasthenia Gravis and Related Disorders held on May 15-17, 2017 in New York. This conference was organized by the Myasthenia Gravis Foundation of America and the New York Academy of Sciences. The study was presented by the principal investigator, by Dr. Linda Kusner of the Laboratory for Myasthenia Gravis Research at George Washington University School of Medicine & Health Sciences.
December 20, 2015
Emerging Health Technologies Can Enhance Canada’s Prosperity
Canadian pharmaceutical company Alpha Cancer Technologies Inc. is developing a way to deliver chemotherapy more effectively and with lower doses so the treatment does not cause toxicity in patients.
May 28, 2014
PolyTherics and Alpha Cancer Technologies Collaborate to Produce Novel Drug Conjugates to Target Tumours
PolyTherics Limited (“PolyTherics”), an Abzena company that provides technologies and services to enable the development of better biopharmaceuticals, today announced a collaboration with Alpha Cancer Technologies Inc. (“ACT”), a Canadian company with a targeted drug delivery platform based on alpha fetoprotein (“AFP”). PolyTherics will produce a range of AFP drug conjugates for ACT to test using its proprietary ThioBridge™ technology.
March 11, 2014
Alpha Cancer To Test Oncology Game Changer
AFP is a carrier protein known for transporting nutrients to rapidly growing fetal cells. Only trace amounts of the protein are found following birth, but importantly, receptors for AFP show up again on cancer cells to help shuttle nutrients to rapidly growing cancer cells.